Here is where you can learn all about the latest BioLegend news and upcoming events.
WALTHAM, Mass.--(BUSINESS WIRE)--Sep. 17, 2021-- PerkinElmer, Inc. (NYSE: PKI) a global leader committed to innovating for a healthier world, today announced it has completed its acquisition of BioLegend, a leading, worldwide provider of life science antibodies and reagents for a total consideration of approximately $5.25 billion.
The acquisition, the largest in PerkinElmer’s history, further expands the Company’s life science franchise into high-growth areas such as cytometry, proteogenomics, multiplex assays, recombinant proteins, magnetic cell separation and bioprocessing.
See all of the BioLegend news articles >>
We love the opportunity to meet our customers online and in-person. Let’s connect virtually or at a local event near you.
It is also an excellent opportunity to learn about how we can partner together to accelerate your research. We also love to hear your feedback about how we’re doing and how are products are performing in your lab. Let’s connect at a local event near you.
See our lineup of upcoming events >>